Condition (MeSH)
Arachnodactyly
ClinicalTrials.gov lists 27 trials for Arachnodactyly or a narrower condition beneath it. Mauna Kea Technologies has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
27 of the 27 trials are tagged with Arachnodactyly itself; the rest are tagged with a narrower condition beneath it.
When did Arachnodactyly trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2014 | 3 |
| 2013 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 27 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Arachnodactyly trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Not applicable | 10 |
| Observational | 15 |
How many Arachnodactyly trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Enrolling by invitation | 1 |
| Completed | 19 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Arachnodactyly trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Mauna Kea Technologies | 2 |
| Başakşehir Çam & Sakura City Hospital | 1 |
| Ciphergen Biosystems | 1 |
| General Committee of Teaching Hospitals and Institutes, Egypt | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Arachnodactyly? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| SHR3824 | 1 |
| D-chiro-inositol | 1 |
| Folic (or folinic) acid | 1 |
| Ezetimibe | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| myoinositol and folic acid | 1 |
| inofolic combi | 1 |
| 1% Metformin | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Arachnodactyly? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Marfan's syndrome in Northern Ireland; an account of thirteen families. | Annals of human genetics | 1958 | Yes |
| Biallelic Loss of Proprioception-Related PIEZO2 Causes Muscular Atrophy with Perinatal Respiratory Distress, Arthrogryposis, and Scoliosis. | American journal of human genetics | 2016 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.